GroupKALSHI

Event GroupKALSHIFinancials

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (in 2026)

Total Volume

$0.00

Events

Markets

Trade on Kalshi

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (in 2026)

Vol

$0.00

Events

Markets

Kalshi

Platform StatsQuick Platform Comparison

Polymarket

markets · $0.00

Kalshi

markets · $0.00

Price Spread

0.0%avg

max 0.0%

Arbitrage

of 0 cross-platform

Price ChartMatched Markets Price Graph

1 market tracked

What will the FDA's decision be on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026?

No data available

Single-Platform Markets(1)

Market	Platform	Price
What will the FDA's decision be on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026?	Kalshi	92%

AI Analysis

Trader mode: Actionable analysis for identifying opportunities and edge

92%

Top Probability

$0.00

Volume

Markets

Platforms

About This Event

FDA decision on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) in 2026 If the FDA's decision on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) is an investigational, once-daily, single-t

AI-generated analysis based on market data. Not financial advice.

Custom AI Analysis Prompt

Tap to expand

Open in:ChatGPT Claude Gemini Grok DeepSeek

**Role:** Expert Prediction Market Analyst & Trader
**Objective:** Analyze the provided betting market data to deliver actionable insights, identify mispricings, and perform scenario analysis.
**Current Date:** Friday, July 10, 2026
**Context:** Prediction markets (Polymarket/Kalshi) are binary option markets where price (1-99) equals implied probability (1%-99%).

---

## 1. Event Snapshot
**Event:** FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (in 2026)
**Category:** Financials | **Status:** active
**Resolution Date:** N/A (Unknown)
**Time Pressure:** Unknown

**Description:** FDA decision on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) in 2026

If the FDA's decision on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. 

Bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) is an investigational, once-daily, single-t

**Resolution Criteria (Sample):**
"If the FDA's decision on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes. Secondary rules: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or"

## 2. Market liquidity & Volume
* **Total Volume:** $0
* **Total Liquidity:** $0
* **Activity Level:** Low Activity (Vol/Liq Ratio: 0.00)

## 3. Market Data (Prices & Odds)
### 1. What will the FDA's decision be on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026?
- **Kalshi** (End: Jan 8, 2027): Vol $0
  DATA: [Yes: 92.0% (0.0%)] | [No: 8.0% (0.0%)]

---

## Analysis Instructions
Please provide a structured analysis using the following template:

### 1. Executive Summary
*   **Verdict:** [Most Likely Outcome]
*   **Confidence:** [0-100]%
*   **Timeframe:** [Immediate / Short-term / Long-term]
*   **Actionable Trade:** [Buy YES / Buy NO / Stay Away] (Include entry price target if applicable)
*   **Rationale:** 2-sentence summary of the core thesis.

### 2. Scenario Analysis
*   **Bull Case (Why YES goes up):** List specific catalysts or data points.
*   **Bear Case (Why YES goes down):** List specifics.
*   **Invalidation Point:** What happens to prove your thesis wrong?

### 3. Market Mechanics & Risks
*   **Liquidity/Volume Analysis:** Is the market efficient? Is it easy to exit?
*   **Cross-Platform Arbitrage:** (If applicable) Is the spread tradeable after fees?
*   **Time Decay:** How does time passing affect this position?

### 4. Signal Scores (0-100)
*   **Momentum:** [Score] (Price trend & velocity)
*   **Conviction:** [Score] (Volume backing the move)
*   **Information Edge:** [Score] (Likelihood of non-public info affecting price)
*   **Risk/Reward:** [Score] (Potential upside vs downside)

**Constraints:**
- Be direct and objective.
- Use bullet points for readability.
- If data is conflicting or insufficient, explicitly state "Low Confidence".

Tap text to select all

Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.

KALSHIFinancials